We exist to alleviate human suffering


Team that makes
everything possible

Core Team

Jen Nwankwo, Ph.D. Founder & CEO
short biography

Before founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.

Bridget Cole, Ph.D. Chief Scientific Officer
short biography

Bridget brings 25 years of drug discovery and clinical development experience having contributed to multiple drug candidates including FDA approved Rezurock™. Previously, she was SVP of Drug Discovery at Nocion Therapeutics where she helped discover and develop clinical candidate NTX-1175. Before Nocion, Bridget held various leadership positions including VP at Flatley Discovery Lab and Surface Logix, and AD at Pfizer.

Brandon Moore, Ph.D. Head of AI Research & ML Engineering
short biography

Brandon harnesses machine learning and parallel computing to design small molecule therapeutics using our AI-powered E​LVIS​™ and ROSALYND​™ platforms.​ He received his Bachelor’s degree in Cognitive Neuroscience from MIT and a Ph.D. in Neuroscience from Vanderbilt where he leveraged neural networks to study the primate visual system. Once a King of the Nerds contestant, Brandon enjoys creative STEM projects like building animatronic chatbots, training generative art algorithms, and teaching monkeys addition (PNAS/I Fing Love Science).

Edward Walker, Ph.D. Director of Protein Therapeutics
short biography

Edward earned his PhD from the University of Cambridge while researching the enzymology of the biotransformation of morphine into hydromorphone, followed by a post-doc at the Laboratory of Molecular Biology in Cambridge, where he solved the structure of PI3K. Since his move into industry, he has spent nearly 25 years concentrating on antibodies at CaT/MedImmune and Isogenica Ltd, and also on peptide drug discovery at Bicycle Therapeutics where, as their first employee, he patented many of their key processes and drugs.

Peter Bertinato, Ph.D. Director of Medicinal Chemistry
short biography

Peter is a seasoned medicinal chemist with over 25 years of experience in drug discovery and development having contributed to the discovery of multiple preclinical and clinical drug candidates including the FDA approved veterinary medicine drug SelentrolTM. Prior to joining 1910 Genetics, Peter served as Director of Medicinal Chemistry at Reverie Labs. Over his career, Peter has held several senior scientist positions at Eisai, Epix and Pfizer in addition to consulting for several small biotech companies and the Cystic Fibrosis Foundation.

Liping Wu, Ph.D. Associate Director of Biology
short biography

Liping received her PhD in cell and molecular biology from the Australian National University. At 1910 Genetics, she manages R&D operations and thrives on assay biology innovations for the ROSALYND TM platforms. Before joining 1910, Liping served as deputy head of R&D at Prestige Biopharmaceuticals USA. Prior to that, she worked at Cell Assay Innovations, Millennium Pharmaceuticals, and Maxthera Pharmaceuticals.

Jesse W. Collins, Ph.D. AI Research Scientist II
short biography

Jesse studied physics at MIT, and earned his Ph.D. from Harvard University, partly supported by an NSF IGERT fellowship in Biomechanics. He was a postdoc on an NIH-funded project in neuron activity recording. He trained AI models for genetics and tissue architecture studies before joining 1910 Genetics as an AI Research Fellow on the CANDID™ platform for small molecule discovery.

Mostafa Abedi, Ph.D. Computational Theoretical Chemist I​
short biography

Mostafa received his Ph.D. from Technical University of Denmark in computational and theoretical Chemistry. He spent several years working as a postdoctoral researcher at Brown University to leverage the power of machine learning techniques to develop efficient and accurate high-dimensional potential energy surfaces. At 1910 Genetics, his work involves utilizing computational chemistry tools to study and design small and large drug molecules with ELVIS™ and ROSALYND™ platforms.

Cole Baker, M.Eng. Machine Learning Engineer II
short biography

Cole studied computer science at MIT where he earned his bachelor’s degree and his M.Eng. while researching at the Pantazis Magnetoencephalography LAB. His work combined machine learning, brain imaging and hyperbolic geometry to identify the first signs of Alzheimer’s Disease and the potential for cognitive trainings to mitigate disease progression. At 1910 Genetics, he works with ELVIS™ and ROSALYND™ platforms to improve training efficiency, maximize model performance, and implement state of the art research.

Reyal Hoxie, Ph.D. Scientist I, Translational Biochemistry & Pharmacology
short biography

Reyal received her Ph.D. in Biochemistry and Biophysics at Brandeis University, where she investigated the energetics of binding for Hsp90 inhibitors and how Hsp90 inhibitors alter the effect of BiP on the conformation of Grp94. At 1910 Genetics, Reyal works on all aspects of our biological automation platform, leveraging state-of-the-art robotics to automate assay development, validation, and scale up for high throughput screening of therapeutics designed by our AI-powered ELVIS™ and ROSALYND™ platforms.

Mahmoud Ebrahimkhani, Ph.D. AI Research Scientist I
short biography

At 1910 Genetics, Mahmoud works on creating generative AI models for structure-based small molecule drug discovery. Mahmoud earned his MS.c. and Ph.D. in Biomedical Engineering from Stony Brook University and pursued his postdoctoral studies at Northwestern University. His expertise encompasses the creation of AI and machine learning workflows for automated disease diagnosis and digital biomarker prediction.

Hao-Wei Pang AI Research Scientist I
short biography

Francis Acquah, Ph.D. Associate Scientist, Biology
short biography

At 1910, Francis works on developing optimized workflows for our biological automation platform that leverages state-of-the-art robotics and software to automate assay development, validation and high-throughput data analysis to support clear decision-making. Francis received his PhD from the University of Oklahoma Health Science Center, Department of Biochemistry where he used integrated computational, biochemical and crystallographic approaches to identify druglike compounds targeting nicotinic receptor and RNA double helices.

Lakshmi Chivukula, Ph.D. Associate Scientist, Biology
short biography

Lakshmi received her Ph.D. in Nanoscience at University of North Carolina Greensboro, where she studied the Interaction mechanism of pathogenic yeast with nanostructured surfaces thereby investigating how such interaction influences the sterol quantity and antifungal drug resistance of pathogenic yeast. At 1910 Genetics, Lakshmi works on developing and validating biochemical and cell-based high throughput screening assays for therapeutics designed by our AI-powered ELVIS™ and ROSALYND™ platforms.

Matthew Sherman Automation Engineer II
short biography

Matt studied biomedical engineering at Stevens Institute of Technology where he earned his bachelor's degree.  He spent the last 7 years working in lab automation and compound management for oncology discovery.  At 1910 Genetics, Matt works on implementing and optimizing automated processes for our biological assays and inventory.

Yujun Tao Computational Theoretical Chemist I
short biography

Sidharth Shankar Research Associate II, Translational Biochemistry & Pharmacology
short biography

At 1910 Genetics, Sidharth works on all aspects of our biological automation platform, which leverages state-of-the-art robotics to automate assay development, validation, and scale up for high throughput screening of therapeutics designed by our AI-powered ELVIS™ and ROSALYND™ platforms. Sidharth received his bachelor’s in Microbiology from the University of Washington, and spent three years in the Otterbein Lab at Harvard Medical School where he investigated the therapeutic potential of low dose carbon monoxide across models of sepsis and traumatic brain injury.

Juan Yancovich Software Engineering Fellow
short biography

Daniel Ramirez Data Engineering Fellow
short biography

Matt McCoy, Ph.D. AI Research Fellow
short biography

Matt has a PhD in Computational Biology and Bioinformatics from George Mason University, where he developed methods to utilize protein structure dynamics to predict the phenotypic result of genomic mutations. He has continued to gain experience integrating AI into bioinformatic and protein structure analysis across a number of biotech applications (microbial characterization, agriculture, healthcare, drug development). At 1910 Genetics, he contributes to the development of the ROSALYND platform.

Yemisi Olorunwunmi Business Operations Associate
short biography

Kyle Barbato Interim Head of Talent Acquisition
short biography

Derron Juarez Lead Recruiter
short biography

Nick Sciuto Senior Recruiter
short biography

Jenna Caminiti Recruiting Coordinator
short biography

Board of Directors and Advisors

Jen Nwankwo, Ph.D. Board Director
short biography

Jen is the Founder & CEO of 1910 Genetics. Before founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.

Shaan Gandhi, MD, DPhil, Ph.D. Board Director
short biography

George Golumbeski, Ph.D. Chairman of the Business Advisory Board
short biography

Trained as a research scientist, George has focused on enabling young, innovation-driven companies to bring breakthrough medications into medical practice. In his more than 25 years leading Business Development organizations, he has contributed to advancement of numerous marketed medications that are benefiting patients worldwide. Known globally for his interest in leading-edge science and his creativity in forging inter-company collaborations, he was recognized in 2014 by Fierce Biotech as one of the 20 most influential people in the Biotechnology industry.

Sam Altman Technology Advisory Board
short biography

Petra Jantzer, Ph.D. Business Advisory Board
short biography

Tom Lounibos Business Advisory Board
short biography

Kailash Swarna, Ph.D. Technology Advisory Board
short biography

Cecil Lynch, MD Technology Advisory Board
short biography

Ted Love, M.D. Business Advisory Board
short biography

Ashish Vaswani, Ph.D. Technology Advisory Board
short biography

Suresh Poda, Ph.D. Scientific Advisory Board
short biography

Suresh is the Vice President of Neuroscience and Preclinical Research at Encoded Therapeutics, a pioneering gene therapy company focusing on neurological diseases. Before joining Encoded, Dr. Suresh held senior research positions at Eisai, Denali, Lundbeck, and started his industry career at AstraZeneca, following a decade of academic research at the University of Michigan and the University of Montreal. He has led numerous drug development programs from discovery through the early clinical stage, focusing on therapies for psychiatry, neurology, and inflammatory diseases.